Cancer Precision Medicine Panel

 
Prev Next

Cancer Precision Medicine Panel

Our Cancer Precision Medicine Panel has been designed to detect a broad range of clinically actionable genomic variants occurring in cancer genes relevant to solid tumour diagnosis, prognosis and treatment.

The panel is designed to accept DNA isolated from a wide range of cancer sample sources and is designed to detect Single Nucleotide Variants (SNVs), insertions and deletions (indels), Copy Number Variants (CNVs), genomic signatures including Microsatellite Instability (MSI) and Loss of Heterozygosity (LOH) in key tumour suppressor genes as well as large-scale structural variants.

Our Design

Our design allows for confident exclusion of key clinically important variants using unique molecular identifiers (UMIs) that permit molecular counting and exclusion of sequence and fixation artefacts.

Variant interpretation and reporting is provided in conjunction with a leading tertiary analysis provider and includes full details of clinically actionable variants detected, variant allele frequencies, licensed therapies appropriate to tumour histology (where provided), relevant National Comprehensive Cancer Network® (NCCN®) guidance and potential eligibility for clinical trials (dependent on clinical eligibility e.g. performance status, previous treatment regimens etc).

Indications Detected

Lung Cancer (NSCLC)

Lung Cancer (NSCLC)

Colorectal Cancer including Lynch syndrome

Colorectal Cancer including Lynch syndrome

Central Nervous System (CNS) tumours

Central Nervous System (CNS) tumours

Melanoma

Melanoma

Breast Cancer

Breast Cancer

Ovarian Cancer

Ovarian Cancer

Sample Type

Yourgene Health | the IONA® test | 99% detection rate

FFPE tissue sections (histology & cytology)

Recommended neoplastic cell content for tissue samples >10%

Reporting and Target Turnaround Time

Yourgene Health | the IONA® test | 99% detection rate
  • Full clinical reporting in conjunction with a leading tertiary analysis provider

  • 14 calendar days or less from receipt of specimen and all required clinical information

Features

  • Next Generation Sequencing detection of SNVs, CNVs & LOH

  • Industry standard Illumina SBS sequencing chemistry

  • Up to 88 genes

  • 1Mb SNP backbone across 22 chromosomes (2467 SNVs)

  • Microsatellite Instability (MSI) characterisation

  • Covers core genes in the NHSE Cancer Test Directory

If you are not sure what option to choose above select the General Inquiry option.
Please enter your message in the box above

If you have a question, need further information, or are interested in using our oncology services, we're here to help.